With regards to the screening phase, in 2019 Page et al. published the interim results of the IMPACT study that showed the association between BRCA2 mutation and both a higher incidence of prostate cancer and a younger age at diagnosis, suggesting the utility of PSA screening in men with this genetic alteration [36]. This evidence concerns the gene BRCA2 and prostate carcinoma.